Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has seen a surge in multi-billion-dollar acquisitions, commercialisation deals, and licensing agreements. These developments have enabled the ADC community to make strides in bringing these therapies to earlier-line treatments and expand their use to wider patient populations.

Returning for its 15th anniversary year, World ADC London is the leading European conference uniting over 1000 ADC enthusiasts to maximise the therapeutic index of ADCs. Whether you are brand new to the field or have over a decade of experience, work in discovery or manufacturing, hold a strategic position or work day-to-day in the lab, this meeting offers something for you!

Take a look at the full agenda here.

Embark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle.

Here are some of the leading minds sharing translatable lessons to advance your pipeline including:

1. Alireza Tafazzol, Senior Scientist II, Oncology Bioinformatics, AbbVie.
2. Osama Chahrour, Principal Scientist, Chemical Development, AstraZeneca.
3. Yu-Shin Hsu, Research Analyst, Independent.
4. Jinwon Jung, Senior Director, Protein Engineering, ABL Bio.
5. Hayley Jackman, Director, CMC Regulatory Affairs, AstraZeneca.
6. Lolke de Haan, Vice President, Toxicology, ADC Therapeutics.
7. Max Lee, Associate Director, AstraZeneca.
8. Paul WolstenholmeHogg, Vice President, Medicinal Chemistry, ADC Therapeutics.
9. Tomohiro Fujii, ADC Researcher, Ajinomoto Bio-Pharma Services.
10. Ying Buechler, Chief Technology Officer, Ambrx, a Johnson & Johnson Company.
11. Paul Jaminet, Chief Executive Officer, Angiex.
12. Uchechukwu OkorjiObike, Senior Scientist, Bioassay Development, AstraZeneca.

See the full speaker faculty and session details here.

Don’t miss this chance to unlock unmissable R&D, focused industry networking opportunities, and emerging trends taking hold of the ADC field with sessions from 120+ world-leading speakers including Daiichi Sankyo, AstraZeneca, Pfizer, AbbVie, Merck, GSK, Johnson & Johnson, ADC Therapeutics and more.